Keywords: roche, xeloda, promising, colorectal, cancer, orally-active, 5-fluorouracil
Roche's Xeloda promising in colorectal cancer
Article | 26 May 1999
Roche's orally-active 5-fluorouracil prodrug Xeloda (capecitabine) hasbeen found to outperform standard treatment with 5-FU and leucovorin in patients with advanced, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
